East Norriton, Penn., May 25, 2017. Responding to increasing pressure to demonstrate value and lower the cost of pharmaceuticals, particularly in today’s uncertain health policy environment, Market Access leaders are investing more in Health Economics & Outcomes Research (HEOR) capabilities and enhanced data and analytics according to research conducted by TGaS® Advisors. Policy is top of mind for these leaders. “Market Access has become center stage as a strategic imperative for the pharmaceutical industry as increased barriers and pricing pressures limit traditional approaches to market growth,” said practice leader Rebecca Villari.
The benchmarking and advisory services firm’s Market Access & Reimbursement practice conducted primary research with 17 stakeholders to learn more about key trends, organizational changes, strategic priorities, budget impact and investment priorities. In an analysis of what has changed from 2016, TGaS found:
- The impact of government policy and influencers, considered secondary last year, is now a major concern. One respondent noted, “We are currently monitoring 44 pieces of legislation in 26 states.”
- Increased restrictions on co-pay support by manufacturers adds to pricing pressure as the need for patient assistance escalates.
- Movement toward value-based contracting has increased. Nearly two-thirds of respondents (59%) saw it as one of the top three key trends.
What hasn’t changed from 2016:
- Payers continue to raise the bar for clinical evidence, including for rare diseases, and emphasize the importance of outcomes data.
- Payers continue to increase utilization management to drive use of preferred products.
- Pricing pressure remains strong.
Talent acquisition was seen as one of the top three strategic imperatives in both 2016 and 2017. As the market access function elevates to a strategic arm of the organization, there is intense competition for highly valued and experienced talent within pharma. One leader commented, “So many channels are evolving at different rates. It becomes exceedingly difficult to find the right talent that has the capability to see interdependencies.”
Investment priorities also show the shift to demonstrating value. Stakeholders are allocating resources to improve the value story and mitigate utilization barriers. While reimbursement programs remain the first investment priority, Contract Strategy and Development, HEOR (previously unranked) and Data and Analytics moved up in the rankings.
For more information on the 2017 Market Access & Reimbursement Landscape, contact Rebecca Villari, Rebecca.Villari@tgas.com
About TGaS® Advisors
TGaS Advisors is the leading benchmarking and advisory services firm for commercial organizations in the life sciences industry. With a roster of top 50, emerging and precommercial life sciences companies, TGaS provides robust comparative intelligence and collaborative network membership services. The team includes more than 60 experienced professionals, most with senior level experience in the life sciences and related industries. To learn more, visit www.tgas.com.
The benchmarking and advisory services firm’s Market Access & Reimbursement practice conducted primary research with 17 stakeholders to learn more about key trends, organizational changes, strategic priorities, budget impact and investment priorities. In an analysis of what has changed from 2016, TGaS found:
- The impact of government policy and influencers, considered secondary last year, is now a major concern. One respondent noted, “We are currently monitoring 44 pieces of legislation in 26 states.”
- Increased restrictions on co-pay support by manufacturers adds to pricing pressure as the need for patient assistance escalates.
- Movement toward value-based contracting has increased. Nearly two-thirds of respondents (59%) saw it as one of the top three key trends.
What hasn’t changed from 2016:
- Payers continue to raise the bar for clinical evidence, including for rare diseases, and emphasize the importance of outcomes data.
- Payers continue to increase utilization management to drive use of preferred products.
- Pricing pressure remains strong.
Talent acquisition was seen as one of the top three strategic imperatives in both 2016 and 2017. As the market access function elevates to a strategic arm of the organization, there is intense competition for highly valued and experienced talent within pharma. One leader commented, “So many channels are evolving at different rates. It becomes exceedingly difficult to find the right talent that has the capability to see interdependencies.”
Investment priorities also show the shift to demonstrating value. Stakeholders are allocating resources to improve the value story and mitigate utilization barriers. While reimbursement programs remain the first investment priority, Contract Strategy and Development, HEOR (previously unranked) and Data and Analytics moved up in the rankings.
For more information on the 2017 Market Access & Reimbursement Landscape, contact Rebecca Villari, Rebecca.Villari@tgas.com
About TGaS® Advisors
TGaS Advisors is the leading benchmarking and advisory services firm for commercial organizations in the life sciences industry. With a roster of top 50, emerging and precommercial life sciences companies, TGaS provides robust comparative intelligence and collaborative network membership services. The team includes more than 60 experienced professionals, most with senior level experience in the life sciences and related industries. To learn more, visit www.tgas.com.
